Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.63 +2.4%	$0.64	$0.51 ▼ $1.80	$60.52M	0.29	657,658 shs	228,019 shs
CYAD Celyad Oncology	$0.60	$0.67	$0.46 ▼ $3.07	$15.91M	N/A	N/A	3,009 shs
NRXP NRx Pharmaceuticals	$3.44	$2.38	$1.10 ▼ $6.01	$59.47M	1.54	413,678 shs	357,688 shs
RPTX Repare Therapeutics	$1.47 +1.2%	$1.30	$0.89 ▼ $4.29	$62.92M	0.84	253,068 shs	37,176 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	-4.52%	-1.19%	-12.52%	-39.24%
CYAD Celyad Oncology	0.00%	0.00%	0.00%	0.00%	0.00%
NRXP NRx Pharmaceuticals	0.00%	+5.20%	+43.33%	+46.38%	+1.78%
RPTX Repare Therapeutics	0.00%	-0.20%	+10.30%	+33.36%	-63.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.2386 of 5 stars	3.5	1.0	0.0	0.0	2.7	0.8	1.3
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	1.9295 of 5 stars	3.6	1.0	0.0	0.0	2.6	0.8	0.6
RPTX Repare Therapeutics	2.7172 of 5 stars	3.3	3.0	0.0	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.75	335.20% Upside
CYAD Celyad Oncology	0.00	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	728.49% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	206.75% Upside

Current Analyst Ratings Breakdown

Latest CYAD, RPTX, ASRT, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
5/13/2025	ASRT Assertio	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
3/31/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/20/2025	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.50

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$119.00M	0.51	$0.56 per share	1.12	$1.46 per share	0.43
CYAD Celyad Oncology	$110K	144.65	N/A	N/A	$0.26 per share	2.31
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.38) per share	N/A
RPTX Repare Therapeutics	$1.07M	58.64	N/A	N/A	$5.03 per share	0.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$331.94M	-$0.32	N/A	21.06	3.25	-54.46%	3.79%	1.81%	8/6/2025 (Estimated)
CYAD Celyad Oncology	-$9.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	-$30.15M	-$2.01	N/A	N/A	N/A	N/A	N/A	-449.16%	8/13/2025 (Estimated)
RPTX Repare Therapeutics	-$93.80M	-$3.01	N/A	N/A	N/A	-99.76%	-40.87%	-35.07%	N/A

Latest CYAD, RPTX, ASRT, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.30	2.01	1.57
CYAD Celyad Oncology	0.26	3.59	N/A
NRXP NRx Pharmaceuticals	N/A	0.20	0.20
RPTX Repare Therapeutics	N/A	6.45	6.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
CYAD Celyad Oncology	N/A
NRXP NRx Pharmaceuticals	4.27%
RPTX Repare Therapeutics	85.09%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
CYAD Celyad Oncology	0.94%
NRXP NRx Pharmaceuticals	19.00%
RPTX Repare Therapeutics	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	95.78 million	92.42 million	Optionable
CYAD Celyad Oncology	95	26.52 million	26.28 million	Not Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	12.72 million	Optionable
RPTX Repare Therapeutics	180	42.89 million	33.33 million	Optionable

CYAD, RPTX, ASRT, and NRXP Headlines

Recent News About These Companies

Repare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% - What's Next?

June 7, 2025 | marketbeat.com

Repare Therapeutics Strengthens Leadership with New Executive Appointment

June 2, 2025 | tipranks.com

MPM Asset Management LLC Has $2.21 Million Stock Position in Repare Therapeutics Inc. (NASDAQ:RPTX)

May 16, 2025 | marketbeat.com

MPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)

May 16, 2025 | marketbeat.com

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 13, 2025 | financialpost.com

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 13, 2025 | financialpost.com

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

Repare Therapeutics Inc. Common Shares (RPTX)

May 2, 2025 | nasdaq.com

Newly Launched DCx Biotherapeutics Inks Licensing Deal With Repare Therapeutics

May 1, 2025 | precisionmedicineonline.com

Why Repare Therapeutics Inc.’s (RPTX) Stock Is Up 5.60%

April 29, 2025 | aaii.com

Cathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare Therapeutics

April 15, 2025 | investing.com

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds

April 1, 2025 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)

April 1, 2025 | markets.businessinsider.com

Repare Therapeutics Names Forte as President, CEO

March 31, 2025 | marketwatch.com

Repare Therapeutics Announces Leadership Transitions

March 31, 2025 | businesswire.com

What Makes Repare Therapeutics (RPTX) a New Buy Stock

March 11, 2025 | zacks.com

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 7, 2025 | businesswire.com

Repare Therapeutics price target lowered to $5 from $10 at H.C. Wainwright

March 7, 2025 | markets.businessinsider.com

Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

March 4, 2025 | uk.finance.yahoo.com

Repare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

March 4, 2025 | finance.yahoo.com

Repare Therapeutics Reduces Workforce by 75 Percent

March 3, 2025 | precisionmedicineonline.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYAD, RPTX, ASRT, and NRXP Company Descriptions

Assertio NASDAQ:ASRT

$0.63 +0.02 (+2.43%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.62 -0.01 (-2.36%)

As of 06/13/2025 07:57 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Celyad Oncology NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

NRx Pharmaceuticals NASDAQ:NRXP

$3.44 0.00 (0.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.44 0.00 (0.00%)

As of 06/13/2025 07:07 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Repare Therapeutics NASDAQ:RPTX

$1.47 +0.02 (+1.17%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$1.44 -0.03 (-1.84%)

As of 06/13/2025 07:19 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time